Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052401 | 0.90 | ALPL (0.35) | TGFBR1CYP3A4CYP2C8GRM5 | |
| SCHEMBL4052659 | 0.85 | ADORA3 (0.39) | TGFBR1CYP3A4 | |
| SCHEMBL4045189 | 0.81 | MEN1 (0.39) | — | |
| SCHEMBL4049910 | 0.78 | GRM5 (0.34) | GRM5 | |
| SCHEMBL4046588 | 0.76 | NISCH (0.32) | — | |
| SCHEMBL4045655 | 0.74 | JAK2 (0.40) | CYP3A4 | |
| SCHEMBL4047454 | 0.73 | IDO1 (0.39) | CYP3A4 | |
| SCHEMBL4047366 | 0.72 | CYP1A2 (0.39) | TGFBR1CYP3A4 | |
| SCHEMBL4051538 | 0.69 | RAD51 (0.39) | GRM5 | |
| SCHEMBL2751962 | 0.67 | TGFBR1 (0.33) | TGFBR1CYP3A4CYP2C8GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20080188507-A1 | Novel azole derivatives | MSD K.K. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7365079-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20060111380-A1 | Novel azole derivatives | MSD K.K. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188507-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | TGFBR1 1025/4885CYP3A4 547/4885CYP2C8 717/4885 |
| US-20060111380-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | TGFBR1 1242/4885CYP3A4 601/4885CYP2C8 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.